Abstract
The reaction of 3-amino-6-methyl-4-phenylpyridine-2(1H)-one with aromatic aldehydes resulted in the corresponding Schiff bases, which reduction with sodium borohydride led to the formation of 3-(arylmethylamino)-6-methyl-4-phenylpyridine-2(1H)-ones. The structure of all prepared compounds was proved by 1H and 13C NMR spectroscopy. The initial evaluation of the synthesized compounds in vivo was carried out for a tranquilizing (anxiolytic) activity by «light–dark box test» and antidepressant activity by Porsolt’s «behavioral despair test». Several derivatives of 3-(arylmethylamino)-6-methyl-4-phenylpyridine-2(1H)-one with higher potential neurotropic activity than that of the comparator drugs (Mexidol and Amitriptyline) were detected.
Graphic abstract
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ballenger JC, Davidson JRT, Lecrubier Y, Nutt DJ, Borkovec TD, Rickels K, Stein DJ, Wittchen HU (2001) Consensus statement on generalized anxiety disorder from the international consensus group on depression and anxiety. J Clin Psychiatr 62:53–58. https://doi.org/10.1159/000201936
Costal B, Jones BJ, Kelly ME, Naylor RJ, Tomkins DM (1989) Exploration of mice in a black and white test box: validation as a model of anxiety. Pharmacol Biochem Behav 32:777–785. https://doi.org/10.1016/0091-3057(89)90033-6
Dillard RD, Easton NR (1996) Acetylenic amines. XIII. syntheses of 3-Carboxy-3-pyrrolin-2-ones. J Org Chem 31:2580–2584. https://doi.org/10.1021/jo01346a031
Fisyuk AS, Kulakov IV, Goncharov DS, Nikitina OS, Bogza YP, Shatsauskas AL (2014) Synthesis of 3-aminopyridin-2(1H)-ones and 1H-pyrido[2,3-b][1,4]oxazin-2(3H)-ones. Chem Heterocycl Compd 50:217–224. https://doi.org/10.1007/s10593-014-1464-9
Kalla R, Strupp M (2019) Aminopyridines and acetyl-DL-leucine: new therapies in cerebellar disorders. Curr Neuropharmacol 17:7–13. https://doi.org/10.2174/1570159x16666180905093535
Kessler RC (2012) The costs of depression. Psychiatr Clin North Am 35:1–14. https://doi.org/10.1016/j.psc.2011.11.005
Kessler RC, Bromet EJ (2013) The epidemiology of depression across cultures. Annu Rev Public Health 34:119–138. https://doi.org/10.1146/annurev-publhealth-031912-114409
Kessler RC, Keller MB, Wittchen HU (2001) The epidemiology of generalized anxiety disorder. Psychiatr Clin North Am 24:19–39. https://doi.org/10.1016/S0193-953X(05)70204-5
Kulakov IV, Nikitina OS, Fisyuk AS, Goncharov DS, Shul’gau ZT, Gulyaev AE (2014) Synthesis and Intramolecular Cyclization of N-acyl- and N-allyl-N’-(2-oxo-1,2-dihydro-pyridin-3-yl)thiourea. Chem Heterocycl Compd 50:670–676. https://doi.org/10.1007/s10593-014-1519-y
Kulakov IV, Matsukevich MV, Shulgau ZT, Sergazy S, Seilkhanov TM, Puzari A, Fisyuk AS (2015) Synthesis and antiradical activity of 4-aryl(hetaryl)-substituted 3-aminopyridin-2(1H)-ones. Chem Heterocycl Compd 51:991–996. https://doi.org/10.1007/s10593-016-1809-7
Kulakov IV, Shatsauskas AL, Matsukevich MV, Palamarchuk IV, Seilkhanov TM, Gatilov YV, Fisyuk AS (2017) A new approach to the synthesis of benzo[c][1,7]naphthyridin-4(3H)-ones. Synthesis 49:3700–3709. https://doi.org/10.1134/S1070428020110019
Kulakov IV, Matsukevich MV, Levin ML, Palamarchuk IV, Seilkhanov TM, Fisyuk AS (2018a) Synthesis of the first representatives of thieno[3,2-c][1,7]naphthyridine derivatives based on 3-amino-6-methyl-4-(thiophen-2-yl)pyridin-2(1H)-one. Synlett 29:1741–1744. https://doi.org/10.1055/s-0037-1610445
Kulakov IV, Palamarchuk IV, Shulgau ZT, Seilkhanov TM, Gatilov YV, Fisyuk AS (2018b) Synthesis, structure and biological activity 3-(arylmethyl) aminopyridine-2 (1H)-ones and 1H-pyrido [2, 3-b][1, 4]oxazin-2 (3H)-ones. J Mol Struct 1166:262–269. https://doi.org/10.1016/j.molstruc.2018.04.036
Kusakabe K, Tada Y, Iso Y, Sakagami M, Morioka Y, Chomei N, Shinonome S, Kawamoto K, Takenaka H, Yasui K, Hamana H, Hanasaki K (2013) Design, synthesis, and binding mode prediction of 2-pyridone-based selective CB2 receptor agonists. Bioorg Med Chem 21:2045–2055. https://doi.org/10.1016/j.bmc.2013.01.006
Ma X, Tan C, Zhu D, Gang DR, Xiao P (2007) Huperzine a from Huperzia species: an ethnopharmacological review. J Ethnopharmacol 113:15–34. https://doi.org/10.1016/j.jep.2007.05.030
Mironov AN, Bunatyan ND et al (2012) Guidelines for conducting preclinical studies of drugs. s. — M.: Grief and K, 1,: 746–758. (In Russ.)
Murray CJL (1996) Lopez AD The Global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Harvard University Press, Cambridge
Murray CJL, Lopez AD (1996) Evidence-based health policy: lessons from the global burden of disease study. Science 274:740–743. https://doi.org/10.1126/science.274.5288.740
Omura S, Sasaki Y, Iwai Y, Takeshima H (1995) Staurosporine, a potentially important gift from a microorganism. J Antibiot 48:535–548. https://doi.org/10.7164/antibiotics.48.535
Porsolt RD (1979) Animal model of depression. Biomed 30(3):139–140
Qian ZM, Ke Y (2014) Huperzine a: is it an effective disease-modifying drug for Alzheimer’s disease? Front Aging Neurosci 6:216–221. https://doi.org/10.3389/fnagi.2014.00216
Ratia M, Giménez-Llort L, Camps P, Muñoz-Torrero D, Pérez B, Clos MV, Badia A (2013) Huprine X and huperzine A improve cognition and regulate some neurochemical processes related with Alzheimer’s disease in triple transgenic mice (3xTg-AD). Neurodegener Dis 11:29–140. https://doi.org/10.1159/000336427
Skolnick AA (1997) Old Chinese herbal medicine used for fever yields possible new Alzheimer disease therapy. JAMA J Am Med Assoc 277:776–778. https://doi.org/10.1001/jama.1997.03540340010004
Spijker J, Graaf R, Bijl RV, Beekman AT, Ormel J, Nolen WA (2004) Functional disability and depression in the general population. Results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Acta Psychiatr Scand 110:208–214
Strasbourg (1986). https://www.coe.int/en/web/conventions/full-list/-/conventions/treaty/123
Tsypysheva IP, Koval’skaya AV, Makara NS, Lobov AN, Petrenko IA, Galkin EG, Sapozhnikova TA, Zarudii FS, Yunusov MS (2012) Synthesis and specific nootropic activity of (–)-cytisine derivatives with carbamide and thiocarbamide moieties in their structure. Chem Nat Compd 48:629–634. https://doi.org/10.1007/s10600-012-0329-7
Tsypysheva IP, Koval’skaya AV, Lobov AN, Makara NS, Petrova PR, Farafontova EI, Zainullina LF, Vakhitova YuV, Zarudii FS (2015) Synthesis and nootropic activity of new 3-amino-12-n-methylcytisine derivatives. Chem Nat Compd 51:910–915. https://doi.org/10.1007/s10600-015-1446-x
Üstün TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ (2004) Global burden of depressive disorders in the year 2000. Br J Psychiatr 184:386–392. https://doi.org/10.1192/bjp.184.5.386
Volchegorskii IA, Miroshnichenko IYu, Rassokhina LM, Faizullin RM, Pryakhina KE (2019) Anxiolytic and Antidepressant Actions of Emoxypine, Reamberin, and Mexidol in Experimental Diabetes Mellitus. Neurosci Behav Physiol 49:136–141. https://doi.org/10.1007/s11055-018-0706-1
Ward A, Brogden RN, Heel RC, Speight TM, Avery GS (1983) Amrinone. A preliminary review of its pharmacological properties and therapeutic use. Drugs 26:468–502. https://doi.org/10.2165/00003495-198326060-00002
Zhang YM, Fan X, Chakaravarty D, Xiang B, Scannevin RH, Huang Z, Ma J, Burke SL, Karnachi P, Rhodesa KJ, Jackson PF (2008) 1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke. Bioorg Med Chem Lett 18:409–413. https://doi.org/10.1016/j.bmcl.2007.10.045
Acknowledgements
The study was carried out with the financial support of the Russian Foundation for Basic Research within the framework of research project No. 18-33-01143 (chemical part) and the Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan under Grant No. AP05131602 (biological part). Spectrophotometric studies were performed on the basis of the Research Resource Center “Natural Resource Management and Physico-Chemical Research” Institute of Chemistry, Tyumen State University (with the financial support of the Ministry of Science and Higher Education of the Russian Federation (Contract No. 05.594.21.0019, unique identification number RFMEFI59420X0019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing financial interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Palamarchuk, I.V., Shulgau, Z.T., Kharitonova, M.A. et al. Synthesis and neurotropic activity of new 3-(arylmethyl)aminopyridine-2(1H)-one. Chem. Pap. 75, 4729–4739 (2021). https://doi.org/10.1007/s11696-021-01696-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11696-021-01696-7